Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
https://www.zacks.com/stock/news/2289934/mustang-mbio-soars-477-on-data-from-rare-blood-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2289934
Jun 18, 2024 - Updated data from a clinical study shows that treatment with Mustang Bio's (MBIO) experimental cell therapy achieved an overall response rate of 90% in patients with a rare form of blood cancer.
0
2 Dividend Stocks That Could Pay You for Life
https://www.fool.com/investing/2024/06/16/2-dividend-stocks-that-could-pay-you-for-life/?source=iedfolrf0000001
Jun 16, 2024 - There are other reasons to love these businesses, too.
0
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
https://www.zacks.com/stock/news/2285380/pharma-stock-roundup-lly-s-cfo-departs-abbv-azn-drugs-get-chmp-approval?cid=CS-ZC-FT-analyst_blog|stock_roundup-2285380
Jun 07, 2024 - Eli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
0
2 High-Yield Dividend Stocks to Buy Right Now
https://www.fool.com/investing/2024/06/05/2-high-yield-dividend-stocks-to-buy-right-now/?source=iedfolrf0000001
Jun 05, 2024 - These two high-yield dividend stocks are top buys right now.
0
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
https://www.zacks.com/stock/news/2282812/abbvie-abbv-skyrizi-gets-chmp-nod-for-ulcerative-colitis-in-eu?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282812
Jun 03, 2024 - AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
0
Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
https://www.zacks.com/stock/news/2282325/gilead-s-gild-urothelial-cancer-study-did-not-meet-its-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282325
May 31, 2024 - Gilead Sciences, Inc.'s (GILD) confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic urothelial cancer fails to achieve its primary endpoint.
0
Are Options Traders Betting on a Big Move in AbbVie (ABBV) Stock?
https://www.zacks.com/stock/news/2280895/are-options-traders-betting-on-a-big-move-in-abbvie-abbv-stock?cid=CS-ZC-FT-tale_of_the_tape|options-2280895
May 29, 2024 - Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.
0
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
https://www.fool.com/investing/2024/05/25/want-decades-of-passive-income-3-stocks-to-buy-now/?source=iedfolrf0000001
May 25, 2024 - These dividend stocks are ideal for investors seeking long-term passive income.
0
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2277858/why-abbvie-abbv-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2277858
May 23, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Lilly (LLY) Hits Record High on Crohn's Disease Study Data
https://www.zacks.com/stock/news/2277543/lilly-lly-hits-record-high-on-crohn-s-disease-study-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2277543
May 22, 2024 - Eli Lilly's (LLY) stock hits an all-time high after announcing detailed results from a late-stage study on mirikizumab in Crohn's disease.
0